Danaher Co. (NYSE:DHR) Shares Sold by Park Place Capital Corp

Park Place Capital Corp lessened its position in shares of Danaher Co. (NYSE:DHR) by 10.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,098 shares of the conglomerate’s stock after selling 122 shares during the quarter. Park Place Capital Corp’s holdings in Danaher were worth $305,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Oak Thistle LLC purchased a new stake in Danaher during the 2nd quarter worth about $363,000. Caden Capital Partners LP increased its position in Danaher by 12.4% during the 4th quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock worth $32,172,000 after purchasing an additional 15,313 shares in the last quarter. HighPoint Advisor Group LLC purchased a new stake in Danaher during the 4th quarter worth about $2,614,000. Norden Group LLC purchased a new stake in Danaher during the 1st quarter worth about $4,151,000. Finally, Duality Advisers LP purchased a new stake in Danaher during the 1st quarter worth about $5,573,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Activity

In other news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. TD Cowen lifted their price objective on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. The Goldman Sachs Group lifted their price target on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Royal Bank of Canada restated an “outperform” rating and issued a $300.00 price target on shares of Danaher in a report on Friday, September 6th. Stephens initiated coverage on Danaher in a report on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 price target for the company. Finally, Barclays lifted their price target on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $282.12.

Danaher Stock Up 0.0 %

NYSE DHR opened at $268.81 on Wednesday. The stock has a market cap of $199.10 billion, a PE ratio of 45.56, a P/E/G ratio of 4.55 and a beta of 0.83. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The business has a 50 day moving average price of $271.01 and a two-hundred day moving average price of $258.75. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.05 EPS. As a group, sell-side analysts predict that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.